Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China
Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are ...
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market
Novo Nordisk A/S (NYSE:NVO) is facing a significant challenge in China, where local pharmaceutical companies are developing ...
Ozempic and Wegovy Are Fueling Novo Nordisk's Business, but Something Else May Be an Even Bigger Growth Driver in the Long Run
Medicare just revised its guidelines to include coverage of Wegovy for patients with cardiovascular complications.
FiercePharma1d
Novo Nordisk highlights the 'Power of Wegovy' in new campaign
According to a Novo announcement unveiling the campaign, the “Power of Wegovy” initiative has a dual-pronged aim: to both ...
Wegovy maker Novo Nordisk sues nine spas, clinics and pharmacies over copycat drugs
Novo Nordisk said on Thursday it had sued nine more medical spas, wellness clinics and pharmacies in the U.S. for selling ...
Ozempic-Maker Novo Nordisk Sues Pharmacies And Weight Loss Clinics For Allegedly Selling Impure Drugs
Novo Nordisk has filed nine lawsuits against medical spas, wellness clinics and pharmacies for allegedly selling impure ...
European stocks higher as markets anticipate first ECB rate cut since 2019; Novo Nordisk up 3.5%
European stocks were higher Thursday, with traders anticipating that the European Central Bank will cut borrowing costs for ...
MM&M1d
Novo Nordisk launches campaign for injectable weight-loss drug Wegovy
Novo Nordisk, the pharmaceutical company behind Ozempic, has launched a national campaign promoting its injectable ...
Novo Nordisk launches national Wegovy® campaign, Power of Wegovy®
Novo Nordisk today launched The Power of Wegovy®, a new national campaign. The campaign aims to educate on the clinical data ...
Novo Nordisk Foundation to Focus on Stem-Cell Therapies in Shift
The Novo Nordisk Foundation, the philanthropic fund behind the maker of blockbuster drugs Ozempic and Wegovy, will give more ...
Where Will Novo Nordisk Be in 10 Years?
Novo Nordisk ( NVO 0.35%) has been a fantastic, market-beating stock to own for the past decade. Its 10-year return is an ...
Nasdaq3d
Ozempic and Wegovy Are Fueling Novo Nordisk's Business, but Something Else May Be an Even Bigger Growth Driver in the Long Run
Novo Nordisk has been exploring a multitude of expanded indications, and earlier this year received some positive news from the Food and Drug Administration (FDA). Specifically, Wegovy was granted ...